Business Context and Reporting Period
Company: ANAPTYSBIO, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: July 28, 2026
Subject: Regulation FD Disclosure regarding the status of consolidated litigation with Tesaro, Inc. and GlaxoSmithKline.
Financial Metrics
This filing is a current report regarding legal proceedings and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event is the conclusion of the trial phase in the consolidated litigation In re Tesaro, Inc. Litigation (C.A. No. 2025-1357-KSJM). The trial was held from July 14-17, 2026. On July 28, 2026, the Court granted a Joint Stipulation and Proposed Order submitted by the Company and the Defendants to govern the post-trial briefing schedule.
Outlook, Risks, and Management Commentary
Legal Proceedings: The Company previously filed a Verified Complaint on November 20, 2025, alleging that Tesaro materially breached the Collaboration and Exclusive License Agreement and that GlaxoSmithKline tortiously interfered with the agreement.
Post-Trial Schedule: Pursuant to the Court-granted Stipulation, the following timeline has been established:
- Company Opening Brief: On or before August 21, 2026.
- Defendants Answering Brief: On or before September 25, 2026.
- Company Reply Brief: On or before October 9, 2026.
- Post-Trial Argument: October 20, 2026.
Key Facts for Investor Verification
- The trial regarding the breach of the Collaboration Agreement with Tesaro has concluded, and the case is now in the post-trial briefing phase.
- The final post-trial argument is scheduled for October 20, 2026, with no judgment date specified in this filing.
- The outcome of this litigation could materially impact the Company's intellectual property rights and potential revenue streams from the Collaboration Agreement.
- No financial data or updated guidance is provided in this specific 8-K filing.